Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Intra-Cellular Therapies Inc (ITCI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.011x
Based on the latest financial reports, Intra-Cellular Therapies Inc (ITCI) has a cash flow conversion efficiency ratio of -0.011x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.08 Million) by net assets ($1.15 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Intra-Cellular Therapies Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Intra-Cellular Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Intra-Cellular Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intra-Cellular Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fortescue Metals Group Ltd
OTCQX:FSUMF
|
0.112x |
|
Dawning Information Industry Co Ltd
SHG:603019
|
0.004x |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
0.099x |
|
Repsol S.A
OTCQX:REPYF
|
0.059x |
|
Repsol SA
OTCQX:REPYY
|
0.059x |
|
Coca-Cola Consolidated Inc.
NASDAQ:COKE
|
-0.283x |
|
ANTA Sports Products Ltd
PINK:ANPDF
|
0.157x |
|
Kasikornbank Public Co Ltd
PINK:KPCPY
|
0.144x |
Annual Cash Flow Conversion Efficiency for Intra-Cellular Therapies Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Intra-Cellular Therapies Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.15 Billion | $-73.18 Million | -0.064x | +69.66% |
| 2023-12-31 | $591.42 Million | $-124.20 Million | -0.210x | +49.01% |
| 2022-12-31 | $656.07 Million | $-270.19 Million | -0.412x | +33.69% |
| 2021-12-31 | $417.89 Million | $-259.54 Million | -0.621x | -77.32% |
| 2020-12-31 | $656.86 Million | $-230.07 Million | -0.350x | +46.63% |
| 2019-12-31 | $195.01 Million | $-127.98 Million | -0.656x | -76.46% |
| 2018-12-31 | $317.71 Million | $-118.17 Million | -0.372x | -109.99% |
| 2017-12-31 | $454.44 Million | $-80.49 Million | -0.177x | +27.12% |
| 2016-12-31 | $375.50 Million | $-91.26 Million | -0.243x | -13.16% |
| 2015-12-31 | $476.24 Million | $-102.28 Million | -0.215x | -13.52% |
| 2014-12-31 | $120.55 Million | $-22.81 Million | -0.189x | +73.52% |
| 2013-12-31 | $31.62 Million | $-22.59 Million | -0.715x | +35.80% |
| 2012-12-31 | $16.98 Million | $-18.90 Million | -1.113x | -222.88% |
| 2011-12-31 | $17.89 Million | $16.20 Million | 0.906x | -- |